Klaria Pharma
Klaria Interim Report
Summary of the interim report
Net sales of 0.0 MSEK (3.7 MSEK)
Other income amounted to 0.3 MSEK (0.0 MSEK)
Second quarter of 2023
- R&D costs for the period amounted to 7.0 MSEK (14.7 MSEK)
- Profit after tax amounted to -10.1 MSEK (14.1 MSEK)
- Earnings per share for the quarter amounted to -0.09 SEK (-0.24 SEK)
- Cash flow from operating activities amounted to -2.2 MSEK (-15.7 MSEK)
- Cash and cash equivalents on the balance sheet date amounted to 8.9 MSEK (7.3 MSEK)
- Cash and cash equivalents on the balance sheet date amounted to 60.6 MSEK (57.7 MSEK)
The period January-June 2023
- Net sales of 6.5 MSEK (3.7 MSEK)
- Other income amounted to 0.3 MSEK (0.4 MSEK)
- R&D costs for the period amounted to 15.6 MSEK (31.8 MSEK)
- Profit after tax amounted to -15.5 MSEK (-34.8 MSEK)
- Earnings per share for the quarter amounted to -0.16 SEK (-0.61 SEK)
- Cash flow from operating activities amounted to -11.3 MSEK (-35.5 MSEK)
| Datum | 2023-08-25, kl 14:30 |
| Källa | Cision |
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 10 000 unika besökare per månad. Vår discord har över 5000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!